PW Medtech Group (FRA:PWE) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PWE PW Medtech Group Ltd FRA:PWE
55 GF Score
Price €0.10
GF Value €0.14
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is PW Medtech Group FFO?

FFO (Funds from operations) only applies to REITs.

FRA:PWE
55GF Score
PW Medtech Group Ltd FRA:PWE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PW Medtech Group (FRA:PWE) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of €0.10 is trading 26.4% below its estimated GF Value™ of €0.14. GuruFocus considers PW Medtech Group to be Modestly Undervalued.

Key valuation signals for FRA:PWE:

  • FFO:
  • GF Value™: €0.14 vs. price of €0.10 (26.4% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PW Medtech Group Business Description

Other Exchanges 01358:Hong Kong
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
55GF Score

Get the complete analysis for FRA:PWE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.14
GF Value